SEGMENTS

We currently manage our operations in two reportable segments, pharmaceuticals and diagnostics. The pharmaceuticals segment consists of two operating segments, our (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products, and vaccines, and (ii) the pharmaceutical operations we acquired in Chile, Mexico, Israel, Spain, Brazil, and Uruguay. The diagnostics segment consists of two operating segments, our (i) pathology operations we acquired through the acquisition of OPKO Lab and (ii) point-of-care and molecular diagnostics operations. There are no inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:



	For the three months ended September 30,						For the nine months ended September 30,
(In thousands)	2014			2013			2014			2013
Product revenues:
Pharmaceuticals	$	17,291		$	16,563		$	58,510		$	50,708
Diagnostics	—			—			—			—
Corporate	—			—			—			—
	$	17,291		$	16,563		$	58,510		$	50,708
Revenue from services:
Pharmaceuticals	$	—		$	—		$	—		$	—
Diagnostics	2,422			2,710			6,426			8,870
Corporate	60			60			180			180
	$	2,482		$	2,770		$	6,606		$	9,050
Revenue from transfer of intellectual property:
Pharmaceuticals	$	—		$	913		$	285		$	14,720
Diagnostics	—			395			191			1,360
Corporate	—			—			—			—
	$	—		$	1,308		$	476		$	16,080
Operating (loss) income:
Pharmaceuticals	$	(34,480	)	$	(11,126	)	$	(71,421	)	$	(7,171	)
Diagnostics	(6,738		)	(399		)	(20,621		)	(16,783		)
Corporate	(6,384		)	(6,606		)	(19,557		)	(17,393		)
Less: Operating loss attributable to noncontrolling interests	(599		)	(879		)	(1,762		)	(2,419		)
	$	(48,201	)	$	(19,010	)	$	(113,361	)	$	(43,766	)
Depreciation and amortization:
Pharmaceuticals	$	1,925		$	2,020		$	6,061		$	5,417
Diagnostics	1,729			1,717			5,136			5,110
Corporate	24			31			72			121
	$	3,678		$	3,768		$	11,269		$	10,648
Revenues:
United States	$	2,482		$	4,078		$	7,082		$	25,130
Chile	7,622			7,993			22,758			24,216
Spain	4,414			4,026			16,230			13,503
Israel	3,710			3,099			14,563			9,666
Mexico	1,528			1,445			4,905			3,323
Other	17			—			54			—
	$	19,773		$	20,641		$	65,592		$	75,838



(In thousands)	September 30, 2014		December 31, 2013
Assets:
Pharmaceuticals	$	1,061,168	$	1,065,033
Diagnostics	109,048		116,944
Corporate	125,026		209,539
	$	1,295,242	$	1,391,516
Goodwill:
Pharmaceuticals	$	173,804	$	175,408
Diagnostics	50,965		50,965
Corporate	—		—
	$	224,769	$	226,373

During the three months ended September 30, 2014, no customer represented more than 10% of our total revenue and during the nine months ended September 30, 2014, one customer represented 13% of our total revenue. During the three and nine months ended September 30, 2013, no customer represented more than 10% of our total revenue.

As of September 30, 2014, no customer represented more than 10% of our accounts receivable balance. As of December 31, 2013, no customer represented more than 10% of our accounts receivable balance.